Australian Capital Territory Numbered Regulations

MEDICINES, POISONS AND THERAPEUTIC GOODS REGULATION 2008 (NO 42 OF 2008) - SCHEDULE 3

Schedule 3     Designated appendix D medicines—standing approvals

(see s 31, s 33, s 41, s 160, s 591, s 592 and s 593)

Part 3.1     Approval conditions

3.1     Definitions—sch 3

In this schedule:

condition 1 , for a doctor prescribing or supplying a designated appendix D medicine to a woman of child-bearing age, means the doctor must ensure that the possibility of pregnancy by the woman has been excluded prior to commencement of treatment.

condition 2 , for a doctor prescribing or supplying a designated appendix D medicine to a woman of child-bearing age, means the doctor must advise the woman to avoid becoming pregnant during, or for a period of 1 month after the completion of, treatment.

condition 3 , for a doctor prescribing or supplying a designated appendix D medicine to a woman of child-bearing age, means the doctor must advise the woman to avoid becoming pregnant during, or for a period of 3 months after the completion of, treatment.

condition 4 , for a doctor prescribing or supplying a designated appendix D medicine to a woman of child-bearing age, means the doctor must advise the woman to avoid becoming pregnant during, or for a period of 24 months after the completion of, treatment.

Part 3.2     Standing approvals for designated appendix D medicines

column 1 item	column 2 doctor	column 3 medicine	column 4 conditions (if any)
1	specialist practising in specialist area of dermatology	acitretin for human use alefacept for human use bexarotene for human use etretinate for human use isotretinoin for human oral use thalidomide for human use	conditions 1 and 4 conditions 1 and 2 conditions 1 and 4 conditions 1 and 2 conditions 1 and 2
2	specialist practising in specialist area of endocrinology, gynaecology or obstetrics	clomiphene for human use cyclofenil for human use dinoprost for human use dinoprostone for human use follitropin alpha (recombinant human follicle-stimulating hormone) for human use follitropin beta (recombinant human follicle-stimulating hormone) for human use luteinising hormone for human use urofollitropin (human follicle-stimulating hormone) for human use
3	specialist practising in specialist area of mental health doctor employed by Territory and working under supervision of chief psychiatrist under Mental Health (Treatment and Care) Act 1994	clozapine for human use
4	specialist physician	acitretin for human use etretinate for human use bexarotene for human use bosentan for human use isotretinoin for human oral use teriparatide for human use thalidomide for human use tretinoin for human oral use	conditions 1 and 4 conditions 1 and 4 conditions 1 and 2 conditions 1 and 3 conditions 1 and 2 conditions 1 and 2 conditions 1 and 2

Note     Specialist includes a doctor training in a specialist area—see the dictionary.